Loading…
Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [11C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic d...
Saved in:
Published in: | The American journal of psychiatry 2004-05, Vol.161 (5), p.826-835 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3 |
---|---|
cites | cdi_FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3 |
container_end_page | 835 |
container_issue | 5 |
container_start_page | 826 |
container_title | The American journal of psychiatry |
container_volume | 161 |
creator | Meyer, Jeffrey H. Wilson, Alan A. Sagrati, Sandra Hussey, Doug Carella, Anna Potter, William Z. Ginovart, Nathalie Spencer, Edgar P. Cheok, Andy Houle, Sylvain |
description | OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [11C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated. METHOD: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects. RESULTS: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses. CONCLUSIONS: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT. |
doi_str_mv | 10.1176/appi.ajp.161.5.826 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71885059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71885059</sourcerecordid><originalsourceid>FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3</originalsourceid><addsrcrecordid>eNp9kdFqFDEUhoNY7Fp9AS8kCHo30yQzycx4t922WihU3BUEkZDJJDbrbBKTjLDP4Qubdbe1eOFNckK-c84PHwAvMCoxbtip8N6UYu1LzHBJy5awR2CGaUWLhpD2MZghhEjR0erzMXga4zo_UdWQJ-AYU0wwq5sZ-LVUwSVnjYWrIGz0LiQV4I2UkxdWbqHT8NL8VHCpRiXTvrrr-Kgmn8R3Ba_srelNciFCkeC50VoFZXPloopv4dzCLxgvvp7Pl2fwg4smBWfhxcbEaHKxchv3LQh_u4XLNA3bZ-BIizGq54f7BHy6vFgt3hfXN--uFvPrQtSMpILJCnVCayFrLNuhYq2qB9IMg0BI5D8shw7JTiKlSY3ahsmeVlU-dN_29SCrE_BmP9cH92NSMfGcSKpxFFa5KfIGty1FtMvgq3_AtZuCzdk4IajuEOl2ENlDMrgYg9LcB7MRYcsx4jtffOeLZ188--KUZ1-56eVh8tRv1PC35SAoA68PgIhSjDo7kiY-4BqGW0Iyd7rn_iy5j_ef1b8BpZGyEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220490299</pqid></control><display><type>article</type><title>Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study</title><source>American Psychiatric Publishing Inc</source><creator>Meyer, Jeffrey H. ; Wilson, Alan A. ; Sagrati, Sandra ; Hussey, Doug ; Carella, Anna ; Potter, William Z. ; Ginovart, Nathalie ; Spencer, Edgar P. ; Cheok, Andy ; Houle, Sylvain</creator><creatorcontrib>Meyer, Jeffrey H. ; Wilson, Alan A. ; Sagrati, Sandra ; Hussey, Doug ; Carella, Anna ; Potter, William Z. ; Ginovart, Nathalie ; Spencer, Edgar P. ; Cheok, Andy ; Houle, Sylvain</creatorcontrib><description>OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [11C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated. METHOD: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects. RESULTS: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses. CONCLUSIONS: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.161.5.826</identifier><identifier>PMID: 15121647</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Antidepressants ; Benzylamines ; Biological and medical sciences ; Carbon Radioisotopes ; Carrier Proteins - drug effects ; Carrier Proteins - metabolism ; Citalopram - pharmacokinetics ; Citalopram - therapeutic use ; Clinical outcomes ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Cyclohexanols - pharmacokinetics ; Cyclohexanols - therapeutic use ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Drug therapy ; Female ; Fluoxetine - pharmacokinetics ; Fluoxetine - therapeutic use ; Humans ; Male ; Medical sciences ; Membrane Glycoproteins - drug effects ; Membrane Glycoproteins - metabolism ; Membrane Transport Proteins ; Mental disorders ; Middle Aged ; Nerve Tissue Proteins ; Neuropharmacology ; Paroxetine - pharmacokinetics ; Paroxetine - therapeutic use ; Pharmacology. Drug treatments ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Serotonin - metabolism ; Serotonin Plasma Membrane Transport Proteins ; Serotonin Uptake Inhibitors - pharmacokinetics ; Serotonin Uptake Inhibitors - therapeutic use ; Sertraline - pharmacokinetics ; Sertraline - therapeutic use ; Tomography ; Tomography, Emission-Computed ; Venlafaxine Hydrochloride</subject><ispartof>The American journal of psychiatry, 2004-05, Vol.161 (5), p.826-835</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright American Psychiatric Association May 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3</citedby><cites>FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.161.5.826$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.5.826$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2855,21626,21627,21628,27924,27925,77794,77799</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15761822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15121647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meyer, Jeffrey H.</creatorcontrib><creatorcontrib>Wilson, Alan A.</creatorcontrib><creatorcontrib>Sagrati, Sandra</creatorcontrib><creatorcontrib>Hussey, Doug</creatorcontrib><creatorcontrib>Carella, Anna</creatorcontrib><creatorcontrib>Potter, William Z.</creatorcontrib><creatorcontrib>Ginovart, Nathalie</creatorcontrib><creatorcontrib>Spencer, Edgar P.</creatorcontrib><creatorcontrib>Cheok, Andy</creatorcontrib><creatorcontrib>Houle, Sylvain</creatorcontrib><title>Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [11C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated. METHOD: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects. RESULTS: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses. CONCLUSIONS: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT.</description><subject>Adult</subject><subject>Antidepressants</subject><subject>Benzylamines</subject><subject>Biological and medical sciences</subject><subject>Carbon Radioisotopes</subject><subject>Carrier Proteins - drug effects</subject><subject>Carrier Proteins - metabolism</subject><subject>Citalopram - pharmacokinetics</subject><subject>Citalopram - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Cyclohexanols - pharmacokinetics</subject><subject>Cyclohexanols - therapeutic use</subject><subject>Delayed-Action Preparations</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fluoxetine - pharmacokinetics</subject><subject>Fluoxetine - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - drug effects</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Membrane Transport Proteins</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Nerve Tissue Proteins</subject><subject>Neuropharmacology</subject><subject>Paroxetine - pharmacokinetics</subject><subject>Paroxetine - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Plasma Membrane Transport Proteins</subject><subject>Serotonin Uptake Inhibitors - pharmacokinetics</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Sertraline - pharmacokinetics</subject><subject>Sertraline - therapeutic use</subject><subject>Tomography</subject><subject>Tomography, Emission-Computed</subject><subject>Venlafaxine Hydrochloride</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kdFqFDEUhoNY7Fp9AS8kCHo30yQzycx4t922WihU3BUEkZDJJDbrbBKTjLDP4Qubdbe1eOFNckK-c84PHwAvMCoxbtip8N6UYu1LzHBJy5awR2CGaUWLhpD2MZghhEjR0erzMXga4zo_UdWQJ-AYU0wwq5sZ-LVUwSVnjYWrIGz0LiQV4I2UkxdWbqHT8NL8VHCpRiXTvrrr-Kgmn8R3Ba_srelNciFCkeC50VoFZXPloopv4dzCLxgvvp7Pl2fwg4smBWfhxcbEaHKxchv3LQh_u4XLNA3bZ-BIizGq54f7BHy6vFgt3hfXN--uFvPrQtSMpILJCnVCayFrLNuhYq2qB9IMg0BI5D8shw7JTiKlSY3ahsmeVlU-dN_29SCrE_BmP9cH92NSMfGcSKpxFFa5KfIGty1FtMvgq3_AtZuCzdk4IajuEOl2ENlDMrgYg9LcB7MRYcsx4jtffOeLZ188--KUZ1-56eVh8tRv1PC35SAoA68PgIhSjDo7kiY-4BqGW0Iyd7rn_iy5j_ef1b8BpZGyEg</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Meyer, Jeffrey H.</creator><creator>Wilson, Alan A.</creator><creator>Sagrati, Sandra</creator><creator>Hussey, Doug</creator><creator>Carella, Anna</creator><creator>Potter, William Z.</creator><creator>Ginovart, Nathalie</creator><creator>Spencer, Edgar P.</creator><creator>Cheok, Andy</creator><creator>Houle, Sylvain</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study</title><author>Meyer, Jeffrey H. ; Wilson, Alan A. ; Sagrati, Sandra ; Hussey, Doug ; Carella, Anna ; Potter, William Z. ; Ginovart, Nathalie ; Spencer, Edgar P. ; Cheok, Andy ; Houle, Sylvain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Antidepressants</topic><topic>Benzylamines</topic><topic>Biological and medical sciences</topic><topic>Carbon Radioisotopes</topic><topic>Carrier Proteins - drug effects</topic><topic>Carrier Proteins - metabolism</topic><topic>Citalopram - pharmacokinetics</topic><topic>Citalopram - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Cyclohexanols - pharmacokinetics</topic><topic>Cyclohexanols - therapeutic use</topic><topic>Delayed-Action Preparations</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fluoxetine - pharmacokinetics</topic><topic>Fluoxetine - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - drug effects</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Membrane Transport Proteins</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Nerve Tissue Proteins</topic><topic>Neuropharmacology</topic><topic>Paroxetine - pharmacokinetics</topic><topic>Paroxetine - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Plasma Membrane Transport Proteins</topic><topic>Serotonin Uptake Inhibitors - pharmacokinetics</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Sertraline - pharmacokinetics</topic><topic>Sertraline - therapeutic use</topic><topic>Tomography</topic><topic>Tomography, Emission-Computed</topic><topic>Venlafaxine Hydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, Jeffrey H.</creatorcontrib><creatorcontrib>Wilson, Alan A.</creatorcontrib><creatorcontrib>Sagrati, Sandra</creatorcontrib><creatorcontrib>Hussey, Doug</creatorcontrib><creatorcontrib>Carella, Anna</creatorcontrib><creatorcontrib>Potter, William Z.</creatorcontrib><creatorcontrib>Ginovart, Nathalie</creatorcontrib><creatorcontrib>Spencer, Edgar P.</creatorcontrib><creatorcontrib>Cheok, Andy</creatorcontrib><creatorcontrib>Houle, Sylvain</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, Jeffrey H.</au><au>Wilson, Alan A.</au><au>Sagrati, Sandra</au><au>Hussey, Doug</au><au>Carella, Anna</au><au>Potter, William Z.</au><au>Ginovart, Nathalie</au><au>Spencer, Edgar P.</au><au>Cheok, Andy</au><au>Houle, Sylvain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>161</volume><issue>5</issue><spage>826</spage><epage>835</epage><pages>826-835</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used [11C]DASB positron emission tomography to measure occupancies of three other selective serotonin reuptake inhibitors (SSRIs) at minimum therapeutic doses. The relationship between dose and occupancy was also investigated. METHOD: Striatal 5-HTT binding potential was measured in 77 subjects before and after 4 weeks of medication administration. Binding potential is proportional to the density of receptors not blocked by medication. Subjects received citalopram, fluoxetine, sertraline, paroxetine, or extended-release venlafaxine. Healthy subjects received subtherapeutic doses; subjects with mood and anxiety disorders received therapeutic doses. Percent reduction in 5-HTT binding potential for each medication and dose was calculated. To obtain test-retest data, binding potential was measured before and after 4 weeks in six additional healthy subjects. RESULTS: Substantial occupancy occurred at subtherapeutic doses for all SSRIs. Compared to test-retest data, each drug at the minimum therapeutic dose had a significant effect on striatal 5-HTT binding potential. Mean occupancy at this dose was 76%-85%. At higher plasma SSRI concentrations, 5-HTT occupancy tended to increase above 80%. For each drug, as the dose (or plasma level) increased, occupancy increased nonlinearly, with a plateau for higher doses. CONCLUSIONS: At tolerable doses, SSRIs have increasing occupancy with increasing plasma concentration or dose. Occupancy of 80% across five SSRIs occurs at minimum therapeutic doses. This suggests that 80% 5-HTT blockade is important for therapeutic effect. Occupancy should be measured during development of antidepressant compounds targeting the 5-HTT.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>15121647</pmid><doi>10.1176/appi.ajp.161.5.826</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 2004-05, Vol.161 (5), p.826-835 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_71885059 |
source | American Psychiatric Publishing Inc |
subjects | Adult Antidepressants Benzylamines Biological and medical sciences Carbon Radioisotopes Carrier Proteins - drug effects Carrier Proteins - metabolism Citalopram - pharmacokinetics Citalopram - therapeutic use Clinical outcomes Corpus Striatum - diagnostic imaging Corpus Striatum - drug effects Corpus Striatum - metabolism Cyclohexanols - pharmacokinetics Cyclohexanols - therapeutic use Delayed-Action Preparations Dose-Response Relationship, Drug Drug therapy Female Fluoxetine - pharmacokinetics Fluoxetine - therapeutic use Humans Male Medical sciences Membrane Glycoproteins - drug effects Membrane Glycoproteins - metabolism Membrane Transport Proteins Mental disorders Middle Aged Nerve Tissue Proteins Neuropharmacology Paroxetine - pharmacokinetics Paroxetine - therapeutic use Pharmacology. Drug treatments Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Serotonin - metabolism Serotonin Plasma Membrane Transport Proteins Serotonin Uptake Inhibitors - pharmacokinetics Serotonin Uptake Inhibitors - therapeutic use Sertraline - pharmacokinetics Sertraline - therapeutic use Tomography Tomography, Emission-Computed Venlafaxine Hydrochloride |
title | Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serotonin%20Transporter%20Occupancy%20of%20Five%20Selective%20Serotonin%20Reuptake%20Inhibitors%20at%20Different%20Doses:%20An%20%5B11C%5DDASB%20Positron%20Emission%20Tomography%20Study&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Meyer,%20Jeffrey%20H.&rft.date=2004-05-01&rft.volume=161&rft.issue=5&rft.spage=826&rft.epage=835&rft.pages=826-835&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.161.5.826&rft_dat=%3Cproquest_cross%3E71885059%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a462t-6c309affac41c8d368e4d27dda00ac301cd90c9c0ef240876cb533cb5fb8b4dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220490299&rft_id=info:pmid/15121647&rfr_iscdi=true |